Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Beata Mladosievicova is active.

Publication


Featured researches published by Beata Mladosievicova.


Journal of Experimental & Clinical Cancer Research | 2012

Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation

Lubica Roziakova; Bojtarova E; Martin Mistrik; Juraj Dubrava; Jozef Gergel; Nadezda Lenkova; Beata Mladosievicova

BackgroundPrevious therapy with anthracyclines (ANT) and conditioning regimen followed by hematopoietic stem cell transplantation (HSCT) represents a high risk for development of cardiotoxicity. The aim of this study was to assess subclinical myocardial damage after HSCT using echocardiography and cardiac biomarkers - high sensitive cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and to identify patients at risk of developing clinical cardiotoxicity.Patients and methodsThirty-seven patients who were treated with allogeneic HSCT for hematologic diseases at median age of 28 years at time of HSCT were studied. Conditioning regimen included either chemotherapy without total body irradiation (TBI) or combination of chemotherapy with TBI. Twenty-nine (78,3%) patients were pretreated with ANT therapy. Cardiac biomarkers were serially measured before conditioning regimen and at days 1, 14 and 30 after HSCT. Cardiac systolic and diastolic functions were assessed before conditioning regimen and 1 month after HSCT by echocardiography.ResultsThe changes in plasma NT-proBNP and hs-cTnT levels during the 30 days following the HSCT were statistically significant (P < 0,01 v.s. P < 0,01). Persistent elevations of NT-proBNP and hs-cTnT simultaneously for a period exceeding 14 days after HSCT were found in 29,7% patients. Serum concentrations of cardiomarkers were significantly elevated in ANT group compared to non-ANT group. These observations were underscored by the echocardiographic studies which did reveal significant changes in systolic and diastolic parameters. Five of 37 (13,5%) patients developed clinical manifestation of cardiotoxicity.ConclusionsElevations in both cardiac biomarkers were found before clinical signs of cardiotoxicity developed. Persistent elevations in NT-pro-BNP and hs-cTnT concentrations simultaneously for a period exceeding 14 days might be used for identification of patients at risk of developing cardiotoxicity and requiring further cardiological follow up.


Journal of Experimental & Clinical Cancer Research | 2012

Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines

Beata Mladosievicova; Dagmar Urbanova; Eva Radvanska; Peter Slavkovsky; Iveta Simkova

BackgroundExposure to anthracyclines (ANT) during childhood represents a high risk for development of late cardiotoxicity. Cardiotoxicity is usually detected only when clinical symptoms or progressive cardiac dysfunction have already occurred. Early detection of cardiotoxicity may lead to better therapeutic outcome. N-terminal pro-brain natriuretic peptide (NTproBNP) has been hypothesized to reflect increased left ventricular wall stress before development of echocardiographic abnormalities. The aim of this study was to detect cardiac abnormalities using plasma NTproBNP and echocardiography in asymptomatic childhood leukemia survivors treated with or without cardiotoxic anthracycline therapy.MethodsSerum levels of NTproBNP were determined in 69 asymptomatic survivors of childhood leukemia treated with or without anthracyclines and in 44 apparently healthy controls. The survivors were divided into two treatment groups: 36 patients after chemotherapy containing anthracyclines (ANT) and 33 patients after chemotherapy without anthracyclines (nonANT). Levels of NTproBNP were measured by using the Elecsys 2010 immunoassay analyzer (Roche Diagnostics). Echocardiography using M-mode, two-dimensional and Doppler measurements were performed on the same day as blood samples were obtained for NTproBNP analysis in survivors.ResultsSerum levels of NTproBNP were significantly higher in the ANT group than in controls (median 51.52 vs 17.37 pg/ml; p=0.0026). Survivors exposed to ANT had significantly increased levels of NTproBNP compared with patients treated without ANT (median 51.52 vs 12.24 pg/ml; p=0.0002). Female exposed and unexposed survivors had significantly higher NTproBNP levels than males. Four of the 36 survivors (11%) treated with ANT and two of the 33 patients (6%) not exposed to ANT had abnormal NTproBNP levels. Although no patient had echocardiographic abnormalities, significant differences were found in values of left ventricular ejection fraction (LVEF) and deceleration time (DT) between survivors treated with or without anthracyclines.ConclusionsHigher levels of NTproBNP detected in childhood leukemia survivors after low anthracycline cumulative doses might reflect an initial stage of ANT cardiotoxicity before the development of echocardiographic abnormalities. Although the current studies support NTproBNP as one of the best available biochemical markers of late anthracycline cardiotoxicity, a possible strategy toward further improvement and combination with other cardiac biomarkers and novel echocardiographic methods should be explored in additional studies.


International Journal of Cardiology | 1996

Signal-averaged ECG in patients with antidepressant therapy

Beata Mladosievicova; Hulín I; Jozef Pogady; Daniela Martisova; Hana Petrasova; Peter Hubka

The signal-averaged electrocardiography (SAECG) identifies patients at risk of ventricular arrhythmias and sudden cardiac death. Since the similarity has been known of the pharmacology of class I antiarrhythmics and tricyclic antidepressants, the potential proarrhythmic effects of antidepressants has become a particular problem. The influence of sodium channel blocking antidepressant drugs on the SAECG time-domain parameters was evaluated, using high-pass filters of 25 Hz and 40 Hz. SAECG was performed in 11 depressed patients with normal cardiac status before and for 4 weeks after antidepressant initiation. At the filter setting of 25 Hz, a significant worsening of all studied SAECG parameters (filtered QRS duration, low-amplitude signal duration, root mean square voltage in the first and in the last 40 ms of the filtered QRS) was found in our patient group. Using a 40 Hz high-pass filter, the results were similar. Antidepressant therapy significantly prolonged filtered QRS duration, significantly reduced root mean square voltages in the first and in the last 40 ms of the filtered QRS and non-significantly prolonged low amplitude signal duration. Amitriptyline and maprotiline induced late potentials (LP) in 2 patients at 40 Hz high pass filter setting. No patient had LP at 25-250 Hz. Our pilot study indicates that sodium channel blocking antidepressant drugs may affect SAECG variables similarly to class I antiarrhythmics. SAECG might be useful in categorizing of antidepressant agents and risk stratification of psychiatric patients.


Oncology Research | 2009

Endocrine Late Effects After Hematopoietic Stem Cell Transplantation

Lubica Roziakova; Beata Mladosievicova

The long-term quality of life of patients after hematopoietic stem cell transplantation (HSCT) represents a multidisciplinary problem. HSCT can induce damage of various organs and tissues-from minimal potentially progressive subclinical changes to life-threatening conditions. Endocrine complications are among the most common late effects observed in survivors after HSCT. The relative risk of these complications is likely to be influenced by the underlying disease, type of therapy, and age at HSCT. Understanding the pathogenetic mechanisms of late complications that can occur after HSCT provides a basis for optimal surveillance and early intervention. Further research is needed for improved risk stratification of patients who are at low and high risk of developing late toxicity. Through collaboration between pathophysiologists, clinicians, and patient associations we can enhance the implementation of prospective studies and set forth effective preventive programs for survivors after HSCT.


Oncology | 2014

Augmenting Clinical Interpretability of Thiopurine Methyltransferase Laboratory Evaluation

Regina Demlová; Mrkvicová M; Jaroslav Sterba; Hana Bernatíková; Jan Stary; Martina Sukova; Alena Mikušková; Alica Chocholova; Beata Mladosievicova; Andrea Soltysova; Darina Behulova; Katerina Pilatova; Lenka Zdrazilova-Dubska; Dalibor Valík

Objective: Individuals with decreased thiopurine methyltransferase (TPMT) activity are at risk of adverse effects of thiopurine administration whereas its increased activity may inactivate drugs faster. We evaluated genotype-phenotype correlations in patients with suspected hematological malignancies and inflammatory bowel disease from our region based on findings of nonlinear TPMT enzyme kinetics previously unreported. Patients and Methods: The study group comprised 267 individuals. They were screened for the most common variants of low TPMT activity. TPMT activity was measured in erythrocytes using the HPLC rate-blanked method. Results: Thirty-three patients (12.4%) were heterozygous (26 were TPMT*1/*3A, 5 TPMT*1/*2, 2 TPMT *1/*3C) and 1 was a compound heterozygote (*2/*3A). Normal and low normal TPMT activities substantially overlapped in wild-type and heterozygous individuals, whereas high activities were found in 29 wild-type genotyped patients. Extreme and life-threatening toxicity was observed in the compound heterozygote patient. Conclusion: Activity measurement performed at diagnosis provides clinicians with information on immediate pharmacokinetic-related adverse events and/or hypermetabolism, and genotyping may indicate the rate of pharmacodynamic thioguanine nucleotide accumulation due to slower overall thiopurine metabolism.


Bratislavské lekárske listy | 2012

Abnormal cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation.

Lubica Roziakova; Bojtarova E; Martin Mistrik; Krajcovicova I; Beata Mladosievicova

OBJECTIVE Clinical cardiac complications in oncologic patients may develop from subclinical myocardial damage. Biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and troponin T (cTnT) have been hypothesized to reflect preclinical cardiotoxicity earlier than echocardiography. The aim of this study was to assess prospectively the serial values of these cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation (HSCT). PATIENTS Twenty-one patients who were treated with allogeneic HSCT for acute leukemia at mean age of 32.8 years (range: 19-58) were studied. The conditioning regimen included high-dose cyclophosphamide in combination with total body irradiation (TBI) or busulphan. All patients were treated with anthracyclines earlier (median cumulative dose 250 mg/m, range: 150-580). METHODS Cardiomarkers were measured before the preparative regimen (PR) and on days 1, 14 and 30 after HSCT. Their cardiac systolic function was assessed before PR, and 1-2 months after HSCT by echocardiography. RESULTS AND CONCLUSION The differences in NT-proBNP before PR and after HSCT were statistically significant (p<0.001). The values of cTnT before and after HSCT were also significantly different (p=0.005). Persistent abnormalities (30 days after HSCT) of NT-proBNP levels were found in 19/21 patients (90.5 %) and of cTnT levels in 10/21 patients (47.6 %). The median cTnT concentrations were higher in patients treated with TBI than in patients without TBI (p=0.013). The median NT-proBNP values were higher in patients pretreated with higher cumulative doses of anthracyclines (>250 mg/m vs ≤250 mg/m) Cardiac symptoms developed in 3/21 (14.3 %) patients (Tab. 1, Fig. 3, Ref. 36).


Pediatric Cardiology | 2001

Frequency-Domain Analysis of the QRS Complex After Treatment of Childhood Cancer with Anthracycline Cytostatics

Beata Mladosievicova; A. Foltinova; I. Luptak; H. Petrasova; Hulín I

Long-term cardiac complications, occurring several years after completion of anticancer treatment, may develop from subclinical myocardial damage induced during cardiotoxic therapy. The aim of this study was to evaluate the usefulness of frequency-domain signal-averaged ECG analysis of the QRS complex for assessing the cardiotoxicity of anthracycline cytostatics. Altogether, 172 signal-averaged electrocardiography (SAECG) registrations were performed in 50 repeatedly evaluated oncologic patients. These registrations were performed 0.2-15 years after completion of anthracycline therapy for childhood cancer. The control group consisted of 120 healthy children and young volunteers; in 20 of these controls, SAECGs were performed repeatedly. Using gliding window fast Fourier transformation within the QRS complex, values area ratio (AR) 60-120 Hz/0-120 Hz were calculated in X, Y, and Z lead. Area ratio of patients after anthracycline therapy was significantly higher than those in control group in X lead. Differences in frequency content in the QRS complex between patients and controls might signal an initial stage of anthracycline-induced myocardial damage.


OncoReview | 2016

QT prolongation due to targeted anticancer therapy

Lucia Setteyova; Ljuba Bacharova; Beata Mladosievicova

A growing number of targeted anticancer agents has shown the unexpected ability to induce QT interval prolongation. In addition, standard chemotherapeutics and a variety of conditions such as electrolyte abnormalities, endocrine disorders, cardiac diseases, nutritional disturbances and other factors may be associated with long QT syndrome in cancer patients. Prolongation of the QT interval can lead to life-threatening ventricular arrhythmias, including ‘torsade de pointes’ (TdP). The association between long QT interval and ventricular arrhythmias remains the subject of many controversies. The QT interval represents the time interval of both ventricular depolarization and repolarization. Not only abnormalities of ion channels, but also changes in the myocardial microarchitecture and other factors and disorders frequently seen in cancer patients may participate in its prolongation and potential risk of ventricular arrhythmias. The aim of this review was to summarize current knowledge about QT prolongation in cancer patients with the special focus on targeted therapy.


Current Cardiology Reports | 2016

The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients.

Barbora Pitekova; Sriram Ravi; Shimoli V. Shah; Beata Mladosievicova; Stephen Heitner; Maros Ferencik

Cardiovascular diseases and cancer represent the two most common causes of morbidity and mortality in industrialized countries. With the increase in long-term survival of cancer patients, cardiovascular diseases are the leading cause of mortality for many cancer survivors. In this article, we will review the most common cardiovascular toxicities of cancer therapies and will describe the role of cardiac CT in the detection and monitoring of cardiovascular disease. While there is limited evidence for the use of CT imaging in cancer patients, we will discuss the utility of cardiac CT in the detection and management of coronary artery disease, pericardial and valvular heart disease.


OncoReview | 2014

Cardiac amyloidosis: a hidden cause of cardiovascular complications in oncology practice

Beata Mladosievicova; Zuzana Poljak; Olja El-Hassoun; Lubica Roziakova; Andrea Carter

Amyloidosis is rare, but known cause of heart failure, cardiomyopathy, coronary artery disease, disorders of cardiac conduction system and valvular damage. Disease often remains undetected until it reaches an advanced stage. Currently, we distinguish several types of amyloidosis. Cardiac amyloidosis may be caused by cancer, chronic inflammation, genetic factors and by aging related processes. Overproduction of amyloidogenic proteins by tumor cells has a key role in the pathogenesis of immunoglobulin light chain amyloidosis. Cardiovascular complications in patients with amyloidosis can be induced by insoluble deposits of misfolded proteins or by direct toxic effects of amyloidogenic molecules on cardiomyocytes and endothelial cells. In this review we focus mainly on pathophysiological mechanisms of cardiac amyloidosis, classification of cardiac amyloidosis types and their cardiovascular manifestations.

Collaboration


Dive into the Beata Mladosievicova's collaboration.

Top Co-Authors

Avatar

Hulín I

Comenius University in Bratislava

View shared research outputs
Top Co-Authors

Avatar

Lubica Roziakova

Comenius University in Bratislava

View shared research outputs
Top Co-Authors

Avatar

Jana Obertova

Comenius University in Bratislava

View shared research outputs
Top Co-Authors

Avatar

Jozef Mardiak

Comenius University in Bratislava

View shared research outputs
Top Co-Authors

Avatar

Katarina Rejlekova

Comenius University in Bratislava

View shared research outputs
Top Co-Authors

Avatar

Michal Mego

Comenius University in Bratislava

View shared research outputs
Top Co-Authors

Avatar

Zuzana Sycova-Mila

Comenius University in Bratislava

View shared research outputs
Top Co-Authors

Avatar

Bojtarova E

Comenius University in Bratislava

View shared research outputs
Top Co-Authors

Avatar

Daniela Svetlovska

Comenius University in Bratislava

View shared research outputs
Top Co-Authors

Avatar

Katarina Kalavska

Comenius University in Bratislava

View shared research outputs
Researchain Logo
Decentralizing Knowledge